Featured Innovation of the Week: the full record is open to everyone.
Clinical Genome-Editing Therapeutics
Delivering CRISPR editors into patients or into their harvested cells makes single-dose, durable correction or silencing of disease-causing genes a treatment modality rather than a laboratory technique.
Developed mainly in: United StatesImpacting: North America, Europe and Rest of Asia
Since we flagged this
First flagged
19 May 2026 · score 9.0/10
Corroborating sources since flagging
78
How the evidence accumulated
Clinical Genome-Editing Therapeutics
20 Jul – 19 Oct
- Findings
- Corroborating sources
- Average disruption of accumulated evidence
Bars count findings and corroborating sources at the moment each was recorded. Scores are model-generated assessments of accumulated evidence and may be incomplete or wrong. Provided for informational purposes only; not investment advice.
First-in-human use of prime editing marks a step-change beyond standard CRISPR, enabling precise multi-base corrections without double-strand breaks and opening a new class of genetic medicine.
Techtimes reported on this innovation separately, on 5 Jul 2026 — reinforcing the signal above rather than just repeating it.
The FDA's expansion of Casgevy to children as young as two marks a critical inflection point for CRISPR therapeutics, unlocking an estimated 5,500 additional patients before organ damage accumulates. Early intervention dramatically improves long-term outcomes, strengthening the commercial case for Vertex and CRISPR Therapeutics. This milestone validates CRISPR as a mainstream curative modality, accelerating payer negotiations and competitive pipeline investment across gene-editing platforms.
Written by Claude, Anthropic's AI model, from the sources behind this trend. How we do it
Forecasted Hypothesis
Signal weakens if
- Extended follow-up reports liver toxicity, off-target editing or waning of the lipid effect beyond 12 months
- The sponsor discontinues or deprioritises the programme in a published trial update or pipeline disclosure
Signal strengthens if
- A randomised Phase 2 trial reports comparable LDL reductions in a larger cohort with no treatment-related serious adverse events
- A regulator grants breakthrough or equivalent designation to an in vivo CRISPR lipid-lowering candidate
Relevant Sources
Authoritative papers, research and reports related to this innovation.
A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity
Jinek, Chylinski, Doudna et al. (Science, 2012)CRISPR Therapeutics — Casgevy (exagamglogene autotemcel) FDA Approval
FDAEducational ResourceCRISPRpedia — Innovative Genomics Institute
UC Berkeley / IGIRelated News
Last 60 days
3 articles
Single CRISPR Infusion Cuts LDL Cholesterol 52% After One Year in Humans
Cleveland Clinic completed a Phase 1 first-in-human trial of a single CRISPR-Cas9 infusion in 15 patients with treatment-resistant lipid disorders. At the highest dose, LDL cholesterol fell 52.5% and triglycerides dropped 47.8% at 12 months with no serious adverse events, suggesting durable, one-shot cardiovascular risk reduction.
Single-dose in vivo CRISPR therapy halves LDL cholesterol for twelve months
Cleveland Clinic investigators reported 12-month follow-up from a first-in-human Phase 1 trial of an infused CRISPR-Cas9 liver gene-editing therapy in 15 patients with drug-refractory lipid disorders. At the top dose, LDL cholesterol fell 52.5% and triglycerides 47.8% from baseline one year after a single infusion, with no treatment-related serious adverse events.
First CRISPR Sickle Cell Patient Victoria Gray Shares Five-Year Outcome Story
Victoria Gray, the first patient to receive CRISPR-based gene editing therapy for sickle cell disease, has spoken publicly about her multi-year experience following treatment. Her case, now over five years post-therapy, highlights the real-world durability of CRISPR editing outcomes in a disease affecting roughly 8 million people globally.
Market Indexes
Innovation-Specific Publicly Listed Stock Symbols
- CRISPR TherapeuticsCRSP · First FDA-approved CRISPR therapy (Casgevy)
- Intellia TherapeuticsNTLA · In vivo CRISPR gene editing
- Editas MedicineEDIT · CRISPR-based medicines pioneer
- Beam TherapeuticsBEAM · Base editing — precision gene editing
- Verve TherapeuticsVERV · CRISPR for cardiovascular disease
Industry-Specific Publicly Listed Stock Symbols
Major companies in the biotech sector.
- AmgenAMGN
- Gilead SciencesGILD
- RegeneronREGN
- Vertex PharmaVRTX
- ModernaMRNA
Biotech Benchmark Indexes & Funds
- NASDAQ Biotechnology^NBI · Biotech-focused NASDAQ index
- SPDR S&P BiotechXBI · Tracks the S&P Biotechnology Select Industry index
- NYSE Arca Pharmaceutical^DRG · Major pharma companies
Prices from Yahoo Finance, delayed. Change over the selected period.
Disclaimer: The information provided on this page is for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities. Stock data shown is illustrative and may not reflect real-time prices. Always conduct your own research and consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.
Institutional & Regulatory Sources
More in Biotech
Other innovations the engine is currently tracking in this industry.
- Virtual Trial Outcome Prediction7.0/ 10 · 2 signals
- Multi-Receptor Incretin Co-Agonists6.8/ 10 · 5 signals
- Programmable RNA And Expression Control7.7/ 10 · 3 signals
- Multivalent Seasonal Respiratory mRNA Vaccines6.5/ 10 · 2 signals
- Novel Food Approval Pathways For Cultivated Meat6.9/ 10 · 7 signals
- Generative Molecular Design Platforms7.0/ 10 · 3 signals
Track every innovation, free for 14 days
Full Analyst access from the first day. No card. Then subscribe to keep it.
- The radar: every innovation, ranked by Disruption Score
- Tracked evolution: score over time, Score Jumps and how the evidence built up
- Thesis and analysis: Commercial Viability, Paradigm Shift, why it matters, what would change it
- Geography: where each innovation is developed and where it has impact
- Exposure: the companies and public stock symbols behind each innovation
- Every signal with its source, and what moved since your last visit
- Email alerts when an innovation moves: First Signal, Score Jump and briefings